Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03260894 · ClinicalTrials.gov registry record · Phase 3
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
A Phase 3 study of Renal Cell Carcinoma (RCC), sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 129
- Enrollment target
- 20
- Study locations
NCT03260894: Completed Phase 3 study of Renal Cell Carcinoma (RCC), sponsored by Incyte Corporation.
NCT03260894 is a Phase 3 study of Renal Cell Carcinoma (RCC) that has completed, run by Incyte Corporation. The registered enrollment target is 129 participants, below the 401-participant average among 12 other Renal Cell Carcinoma (RCC) trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03260894, a Phase 3 study of Renal Cell Carcinoma (RCC), has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 129 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.
Primary Outcome
ORR was defined as the percentage of participants who had complete response (CR) or partial response (PR) per RECIST v1.1 by investigator determination.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Epacadostat
- DRUG Sunitinib
- DRUG Pazopanib
Study Locations (20)
Arizona
- Pinnacle Oncology Hematology - Scottsdale
- Scottsdale Healthcare - Scottsdale
- Arizona Oncology Associates PC- HOPE - Tucson
California
- Cedars-Sinai Medical Center - Los Angeles
- UC Irvine Comprehensive Cancer Center/Chao Family Comprehensive Cancer Center - Orange
- UC Davis Comprehensive Cancer Center - Sacramento
Georgia
- Northside Hospital - Atlanta
- Atlanta Cancer Care - Conyers - Conyers
- Northwest Georgia Oncology Centers Pc - Marietta
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
New York
- New York Oncology Hematology P.C - Albany
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- University of Tennessee Erlanger Oncology & Hematology - Chattanooga
- The West Clinic, P.C. - Germantown
Florida
- Woodlands Medical Specialists, PA - Pensacola
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2017-12-07 |
| Est. Completion | 2025-06-04 |
| Phase | Phase 3 |
What the finished NCT03260894 record still lists
NCT03260894 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 401-participant average among 12 other Renal Cell Carcinoma (RCC) trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Renal Cell Carcinoma (RCC) appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03260894 names 20 study sites across 11 states, led by Arizona, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT03260894 about?
NCT03260894 is a clinical study titled "Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)". The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.
What is the current status of trial NCT03260894?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 129 participants. The study started on 2017-12-07. Estimated completion is 2025-06-04.
What conditions does trial NCT03260894 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma (RCC).
What interventions are being tested in trial NCT03260894?
The interventions under investigation include: Pembrolizumab (DRUG), Epacadostat (DRUG), Sunitinib (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT03260894?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03260894 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma (RCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03260894's enrollment target sits among peer trials
129 6th of 12 higher than 7 of 12 other Renal Cell Carcinoma (RCC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma (RCC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RECRUITING · Phase 3
-
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
COMPLETED · Phase 3
-
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
RECRUITING · NA
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
Investigation of Lymph Node Biology in Kidney Cancer
RECRUITING · NA
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI